Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
THRD Stock | USD 12.76 0.35 2.67% |
About 67% of Third Harmonic's investor base is looking to short. The analysis of the overall investor sentiment regarding Third Harmonic Bio suggests that many traders are alarmed. The current market sentiment, together with Third Harmonic's historical and current headlines, can help investors time the market. In addition, many technical investors use Third Harmonic Bio stock news signals to limit their universe of possible portfolio assets.
Third |
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SADMAD clinical trial initiated and subject screening underway, with results...
Read at globenewswire.com
Third Harmonic Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Third Harmonic can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Third Harmonic Fundamental Analysis
We analyze Third Harmonic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Third Harmonic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Third Harmonic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Third Harmonic is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Third Harmonic Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Third Harmonic stock to make a market-neutral strategy. Peer analysis of Third Harmonic could also be used in its relative valuation, which is a method of valuing Third Harmonic by comparing valuation metrics with similar companies.
Peers
Third Harmonic Related Equities
PASG | Passage Bio | 68.66 | ||||
GLUE | Monte Rosa | 13.72 | ||||
RLYB | Rallybio Corp | 6.36 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
HOWL | Werewolf Therapeutics | 1.52 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
ACRV | Acrivon Therapeutics, | 0.80 | ||||
NUVB | Nuvation Bio | 0.35 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
NXTC | NextCure | 2.50 | ||||
SNSE | Sensei Biotherapeutics | 3.57 | ||||
ELYM | Eliem Therapeutics | 5.88 |
Complementary Tools for Third Stock analysis
When running Third Harmonic's price analysis, check to measure Third Harmonic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Third Harmonic is operating at the current time. Most of Third Harmonic's value examination focuses on studying past and present price action to predict the probability of Third Harmonic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Third Harmonic's price. Additionally, you may evaluate how the addition of Third Harmonic to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |